Cardiac-renal-hepatic-metabolic disease in chronic heart failure (CARMEN-CHF): rationale and design of an observational multicenter prospective study

Components of cardiac-renal-hepatic-metabolic disease (CRHMD), such as atherosclerotic cardiovascular diseases combined with obesity, type 2 diabetes, chronic kidney disease, and metabolic-associated fatty liver disease, are widespread in the general population and are characterized by an unfavorable prognosis. Moreover, there are common mechanisms for the simultaneous involvement of various organs and systems in the pathological process, forming the CRHMD complex. Despite the proven association between the components of the CRHMB and the risk of developing and progressing to a more severe heart failure (HF) course, studies of their combinations in real-world practice are extremely limited. Cardiac-renal-hepatic-metabolic disease in chronic heart failure (CARMEN-CHF) is a multicenter observational study specifically designed to evaluate the incidence of CRHMD and its components in outpatients and hospitalized patients with verified pre-existing or clinically evident HF. The prospective design with a 2-year follow-up period will allow us to evaluate not only the baseline but also the cumulative incidence of CRHMD and its components over time, their prognostic significance in HF course, as well as the potential of modern therapy in reducing the risk of adverse cardiovascular events and death in various HF phenotypes. The role of drugs with proven cardiac-renal-hepatic-metabolic protective properties used in real-world practice on the course and prognosis of both HF and the main components of the CRHMD will be assessed.

1. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021; 61(4):4-14. (In Russ.) doi:10.18087/cardio.2021.4.n1628.

2. Garganeeva AA, Tukish OV, Vitt KN, et al. Chronic Heart Failure in Patients Hospitalized in 2002 and 2021: Comparative Analysis of Prevalence, Clinical Course and Drug Therapy. Kardiologiia. 2024;64(3):3-10. (In Russ.) doi:10.18087/cardio.2024.3.n2595.

3. Soloveva AE, Gorbacheva TV, Solovev AE, et al. Cumulative Incidence and Prognostic Value of Readmissions in Patients With Heart Failure: Data From a Large Cohort Study of Real Clinical Practice in St. Petersburg. Kardiologiia. 2024;64(11):96-105. (In Russ.) doi:10.18087/cardio.2024.11.n2781.

4. Soloveva AE, Medvedev AE, Lubkovsky AV, et al. Total, ageand sex-specific mortality after discharge of patients with heart failure: the first large-scale cohort real-world study on Russian population. Russian Journal of Cardiology. 2024;29(6):5940. (In Russ.) doi:10.15829/1560-4071-2024-5940. EDN: CTTQTF.

5. Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572-80. doi:10.1016/S0140-6736(17)32520-5.

6. Shlyakhto EV, Belenkov YuN, Boytsov SA, et al. Characteristics and outcomes in outpatients with heart failure in Russia: results of a large-scale prospective observational multicenter registry study PRIORITY-HF. Russian Journal of Cardiology. 2025;30(11S):6516. (In Russ.) doi:10.15829/1560-4071-2025-6516. EDN: DZOXMG.

7. Screever EM, van der Wal MHL, van Veldhuisen DJ, et al. Comorbidities complicating heart failure: changes over the last 15 years. Clin Res Cardiol. 2023;112(1):123-33. doi:10.1007/s00392-022-02076-1.

8. Ndumele CE, Rangaswami J, Chow SL, et al.; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023; 148(20):1606-35. doi:10.1161/CIR.0000000000001184.

9. Ostrominski JW, Arnold SV, Butler J, et al. Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020. JAMA Cardiol. 2023;8(11):1050-60. doi:10.1001/jamacardio.2023.3241.

10. Ostrominski JW, Claggett BL, Miao ZM, et al. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis. J Am Coll Cardiol. 2024;84(2):223-8. doi:10.1016/j.jacc.2024.05.005.

11. Fomin IV, Mareev VYu, Ageev FT, et al. Diabetes mellitus as an etiological cause of CHF in the European part of Russian Federation (EPOCHA trial, hospital stage). Russian Heart Failure Journal. 2012;13(1):3-8. (In Russ.)

12. Minhas AMK, Bhopalwala HM, Dewaswala N, et al. Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection Fraction. Curr Probl Cardiol. 2023;48(8):101199. doi:10. 1016/j.cpcardiol.2022.101199.

13. Huang ZM, Chen WR, Su QW, et al. Prognostic Impact of Metabolic Syndrome in Patients With Heart Failure: A Meta-Analysis of Observational Studies. Frontiers in Cardiovasc Med. 2021; 8:704446. doi:10.3389/fcvm.2021.704446.

14. Bánfi-Bacsárdi F, Kazay Á, Gergely TG, et al. Therapeutic Consequences and Prognostic Impact of Multimorbidity in Heart Failure: Time to Act. J Clin Med. 2024;14(1):139. doi:10.3390/jcm14010139.

15. Zannad F, Sanyal AJ, Butler J, et al. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nat Med. 2024;30(9):2423-31. doi:10.1038/s41591-024-03223-z.

16. Salah HM, Pandey A, Soloveva A, et al. Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci. 2021;6(11):918-32. doi:10. 1016/j.jacbts.2021.07.010.

17. Ivashkin VT, Maevskaya MV, Zharkova MS, et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104-40. (In Russ.) doi:10.22416/1382-4376-2022-32-4-104-140. EDN: EXTLXM.

18. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031.

19. Raikhelson KL, Maevskaya MV, Zharkova MS, et al. Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):35-44. (In Russ.) doi:10.22416/1382-4376-2024-961.

20. Spertus JA, Jones PG. Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qual Outcomes. 2015;8(5):469-76. doi:10.1161/CIRCOUTCOMES.115.001958.

21. Krasnitskyi VB, Aronov DM, Dzhankhotov SO. Physical activity assessment in coronary heart disease patients: questionnaire ODA-23+. Cardiovascular Therapy and Prevention. 2011;10(8): 90-7. (In Russ.)

22. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1(2):113-9. doi:10.3109/08037059209077502.

23. Ageev FT, Blankova ZN, Svirida ON, et al. Registry Study "HOSTA CHF": Characterization of the State of the Chronic Heart Failure Treatment Delivery System in Russian Federation Regions: Revealing, Diagnostics, Treatment, Observation. Kardiologiia. 2025; 65(5):3-8. (In Russ.) doi:10.18087/cardio.2025.5.n2922.

24. Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) doi:10.15829/1560-4071-2024-6162. EDN: WKIDLJ.

25. Mareev YuV, Garganeeva AA, Tukish OV, et al. Difficulties in diagnosis of heart failure with preserved ejection fraction in clinical practice: dissonance between echocardiography, NTproBNP and H2HFPEF score. Kardiologiia. 2019;59(12S):37-45. (In Russ.) doi:10.18087/cardio.n695.

26. Arutyunov GP, Kononov SK, Novitskii NI, et al. Possibilities of Optimizing Drug Therapy for Myocardial Infarction: a Consensus on the Use of Type 2 Sodium-Glucose Co-Transporter Inhibitors. Conciliation Document of the Expert Group. Kardiologiia. 2025;65(3):35-47. (In Russ.) doi:10.18087/cardio.2025. 3.n2890.

27. Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16(1):130. doi:10.1186/s12916-018-1103-x.

28. Shlyakhto EV, Arutyunov GP, Batyushin MM, et al. Interim analysis of prospective observational multicenter study of patients with hypertension and chronic kidney disease in the Russian Federation (PRIORITY-CKD). Russian Journal of Cardiology. 2025;30(11S):6515. (In Russ.) doi:10.15829/1560-4071-2025-6515. EDN: DMFDJM.

29. Shlyakhto EV, Belenkov YuN, Boytsov SA, et al. Prevalence, clinical and prognostic role of type 2 diabetes in patients with heart failure: a subanalysis of the PRIORITY-HF study. Russian Journal of Cardiology. 2025;30(11S):6519. (In Russ.) doi:10.15829/1560-4071-2025-6519. EDN: PTVUVL

30. Inciardi RM, Mantovani A, Targher G. Non-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure. Curr Heart Fail Rep. 2023;20(4):308-19. doi:10.1007/s11897-023-00613-1.

31. Drapkina OM, Zyatenkov EV. The involvement of kidneys in chronic heart failure patients with liver steatosis. Cardiovascular Therapy and Prevention. 2016;15(1):26-30. (In Russ.) doi:10.15829/1728-8800-2016-1-26-30.

32. Zhang Z, Wang P, Guo F, et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. J Int Med Res. 2018;46(9):3959-69. doi:10.1177/ 0300060518782780.

33. Statsenko ME, Turkina SV, Fabritskaya SV, et al. The effect of non-alcoholic fatty liver disease on the functional state of the kidneys in patients with chronic heart failure. Experimental and Clinical Gastroenterology. 2021;(10):35-42. (In Russ.) doi:10.31146/1682-8658-ecg-194-10-35-42.